Comparative Pharmacology
Head-to-head clinical analysis: ETHRANE versus FLUOTHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHRANE versus FLUOTHANE.
ETHRANE vs FLUOTHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
None Documented
None Documented
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
Category C
Category C
General Anesthetic
General Anesthetic